<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36844201</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC).</ArticleTitle><Pagination><StartPage>1122529</StartPage><MedlinePgn>1122529</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1122529</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2023.1122529</ELocationID><Abstract><AbstractText>Post-acute sequelae of COVID (PASC), or long COVID, is a multisystem complication of SARS-CoV-2 infection that continues to debilitate millions worldwide thus highlighting the public health importance of identifying effective therapeutics to alleviate this illness. One explanation behind PASC may be attributed to the recent discovery of persistent S1 protein subunit of SARS-CoV-2 in CD16+ monocytes up to 15 months after infection. CD16+ monocytes, which express both CCR5 and fractalkine receptors (CX3CR1), play a role in vascular homeostasis and endothelial immune surveillance. We propose targeting these receptors using the CCR5 antagonist, maraviroc, along with pravastatin, a fractalkine inhibitor, could disrupt the monocytic-endothelial-platelet axis that may be central to the etiology of PASC. Using five validated clinical scales (NYHA, MRC Dyspnea, COMPASS-31, modified Rankin, and Fatigue Severity Score) to measure 18 participants' response to treatment, we observed significant clinical improvement in 6 to 12 weeks on a combination of maraviroc 300 mg per oral twice a day and pravastatin 10 mg per oral daily. Subjective neurological, autonomic, respiratory, cardiac and fatigue symptoms scores all decreased which correlated with statistically significant decreases in vascular markers sCD40L and VEGF. These findings suggest that by interrupting the monocytic-endothelial-platelet axis, maraviroc and pravastatin may restore the immune dysregulation observed in PASC and could be potential therapeutic options. This sets the framework for a future double-blinded, placebo-controlled randomized trial to further investigate the drug efficacy of maraviroc and pravastatin in treating PASC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Patterson, Yogendra, Guevara-Coto, Mora-Rodriguez, Osgood, Bream, Parikh, Kreimer, Jeffers, Rutland, Kaplan and Zgoda.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Bruce K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>IncellDX Inc., San Carlos, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yogendra</LastName><ForeName>Ram</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Beth Israel Lahey Health, Burlington, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guevara-Coto</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Cirug&#xed;a y C&#xe1;ncer (CICICA), Universidad de Costa Rica, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora-Rodriguez</LastName><ForeName>Rodrigo A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Lab of Tumor Chemosensitivity, CIET/DC Lab, Faculty of Microbiology, Universidad de Costa Rica, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osgood</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine, St. Francis Medical Center, Trenton, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bream</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Novant Health Kernersville Medical Center, Kernersville, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parikh</LastName><ForeName>Purvi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Allergy and Immunology, NYU Langone Tisch Hospital, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreimer</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, New York Presbyterian Hospital, Brooklyn, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeffers</LastName><ForeName>Devon</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Stamford Hospital, Stamford, CT, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutland</LastName><ForeName>Cedric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rutland Medical Group, Newport Beach, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Community and Family Medicine, Georgetown University Medical Center, Washington, DC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zgoda</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Creighton University School of Medicine, Phoenix, AZ, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Front Med (Lausanne). 2024 May 15;11:1375607. doi: 10.3389/fmed.2024.1375607</RefSource><PMID Version="1">38813382</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CCR5 antagonist</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">fractalkine (CX3CR1)</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">maraviroc</Keyword><Keyword MajorTopicYN="N">statins</Keyword></KeywordList><CoiStatement>IncellDX holds the patent for the use of CCR5 antagonists (maraviroc) in COVID and long COVID. was employed by IncellDX Inc. BP, RY, PP, JB, EO, DJ, CR, and MK were independent contractors of the CCTC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>27</Day><Hour>4</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36844201</ArticleId><ArticleId IdType="pmc">PMC9944830</ArticleId><ArticleId IdType="doi">10.3389/fmed.2023.1122529</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soriano J, Murthy S, Marshall J, Relan P, Diaz J. Who Clinical Case Definition Working Group on Post-Covid-19 Condition. A clinical case definition of Post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. (2021) S1473-3099:703&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H, Assaf G, McCorkell L, Wei H, Low R, Re&#x2019;em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. (2021) 38:101019. 10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak P, Mukerji S, Alabsi H, Systrom D, Marciano S, Felsenstein D, et al. multisystem involvement in post-acute sequelae of coronavirus disease 19. Ann Neurol. (2021) 91:367&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9011495</ArticleId><ArticleId IdType="pubmed">34952975</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B, Francisco E, Yogendra R, Long E, Pise A, Rodrigues H, et al. Persistence of SARS-CoV2-2 S1 protein in CD16+ monocytes in post-acute sequelae of covid-19 (PASC) up to 15 months post-infection. Front Immunol. (2022) 12:746021. 10.3389/fimmu.2021.746021</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.746021</ArticleId><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas G, Tacke R, Hedrick C, Hanna R. Nonclassical patrolling monocyte function in the vasculature. Arterioscler Thromb Vasc Biol. (2015) 35:1306&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4441550</ArticleId><ArticleId IdType="pubmed">25838429</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapellos T, Bonaguro L, Gem&#xfc;nd I, Reusch N, Saglam A, Hinkley E, et al. Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Front Immunol. (2019) 10:2035. 10.3389/fimmu.2019.02035</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02035</ArticleId><ArticleId IdType="pmc">PMC6728754</ArticleId><ArticleId IdType="pubmed">31543877</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber C, Belge KU, Hundelshausen P v, Draude G, Steppich B, Mack M, et al. Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol. (2000) 67:699&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">10811011</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Guevara-Coto J, Yogendra R, Francisco EB, Long E, Pise A, et al. Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning. Front Immunol. (2021) 12:700782. 10.3389/fimmu.2021.700782</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.700782</ArticleId><ArticleId IdType="pmc">PMC8273732</ArticleId><ArticleId IdType="pubmed">34262570</ArticleId></ArticleIdList></Reference><Reference><Citation>Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. (2004) 16:1201&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">15337520</ArticleId></ArticleIdList></Reference><Reference><Citation>Vangelista L, Vento S. The expanding therapeutic perspective of CCR5 blockade. Front Immunol. (2018) 8:1981. 10.3389/fimmu.2017.01981</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01981</ArticleId><ArticleId IdType="pmc">PMC5770570</ArticleId><ArticleId IdType="pubmed">29375583</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques R, Guabiraba R, Russo R, Teixeira M. Targeting CCL5 in inflammation. Expert Opin Ther Targets. (2013) 17:1439&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7103722</ArticleId><ArticleId IdType="pubmed">24090198</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari J, et al. CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. Int J Infect Dis. (2021) 103:25&#x2013;32. 10.1016/j.ijid.2020.10.101</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.10.101</ArticleId><ArticleId IdType="pmc">PMC7654230</ArticleId><ArticleId IdType="pubmed">33186704</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen G, Borgland S, Lam M, Libermann T, Wong N, Muruve D. Adenovirus vector-induced inflammation: capsid-dependent induction of the C-C chemokine RANTES requires NF-kappa B. Hum Gene Ther. (2002) 13:367&#x2013;79. 10.1089/10430340252792503</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/10430340252792503</ArticleId><ArticleId IdType="pubmed">11860704</ArticleId></ArticleIdList></Reference><Reference><Citation>Arberas H, Guardo AC, Bargall&#xf3; ME, Maleno MJ, Calvo M, Blanco JL, et al. In vitro effects of the CCR5 inhibitor maraviroc on human T cell function. J Antimicrob Chemother. (2013) 68:577&#x2013;86. 10.1093/jac/dks432</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dks432</ArticleId><ArticleId IdType="pubmed">23152485</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozo-Balado MM, Rosado-S&#xe1;nchez I, M&#xe9;ndez-Lagares G, Rodr&#xed;guez-M&#xe9;ndez MM, Ruiz-Mateos E, Benhnia MR, et al. Maraviroc contributes to the restoration of the homeostasis of regulatory T-cell subsets in antiretroviral-naive HIV-infected subjects. Clin Microbiol Infect. (2016) 22:e1&#x2013;5. 10.1016/j.cmi.2015.12.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2015.12.025</ArticleId><ArticleId IdType="pubmed">26806257</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimato T, Palka B. Fractalkine (CX3CL1), GM-CSF and VEGF-A levels are reduced by statins in adult patients. Clin Transl Med. (2014) 3:14. 10.1186/2001-1326-3-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2001-1326-3-14</ArticleId><ArticleId IdType="pmc">PMC4067646</ArticleId><ArticleId IdType="pubmed">24995121</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanner MF. Python: a programming language for software integration and development. J Mol Graph Model. (1999) 17:57&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10660911</ArticleId></ArticleIdList></Reference><Reference><Citation>Mckinney W.
pandas: a foundational python library for data analysis and statistics. (2021). Available online at: http://pandas.sf.net
(accessed April 17, 2021)</Citation></Reference><Reference><Citation>Virtanen P, Gommers R, Oliphant T, Haberland M, Reddy T, Cournapeau D, et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods. (2020) 17:261&#x2013;72. 10.1038/s41592-019-0686-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0686-2</ArticleId><ArticleId IdType="pmc">PMC7056644</ArticleId><ArticleId IdType="pubmed">32015543</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihaka R, Gentleman RR. A language for data analysis and graphics. J Comput Graph Stat. (1996) 5:299&#x2013;314. 10.1080/10618600.1996.10474713</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10618600.1996.10474713</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla NV, Bowyer K, Hall L, Kegelmeyer WP. SMOTE: synthetic minority over-sampling technique. J Artif Intell Res (2002) 16:321&#x2013;57. 10.1613/jair.953</Citation><ArticleIdList><ArticleId IdType="doi">10.1613/jair.953</ArticleId></ArticleIdList></Reference><Reference><Citation>Modified Rankin Score (MRS).
Specifications manual for joint commission national quality measures (v2018A). (2022). Available online at: https://manual.jointcommission.org/releases/TJC2018A/DataElem0569.html
(accessed February 3, 2022).</Citation></Reference><Reference><Citation>Sletten D, Suarez G, Low P, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated composite autonomic symptom score. Mayo Clin Proc. (2012) 87:1196&#x2013;201. 10.1016/J.MAYOCP.2012.10.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MAYOCP.2012.10.013</ArticleId><ArticleId IdType="pmc">PMC3541923</ArticleId><ArticleId IdType="pubmed">23218087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasama T, Wakabayashi K, Sato M, Takahashi R, Isozaki T. Relevance of the CX3CL1/Fractalkine-CX3CR1 pathway in vasculitis and vasculopathy. Transl Res. (2010) 155:20&#x2013;6. 10.1016/j.trsl.2009.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2009.08.009</ArticleId><ArticleId IdType="pubmed">20004358</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. (2008) 28:403&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">18174460</ArticleId></ArticleIdList></Reference><Reference><Citation>Flierl U, Bauersachs J, Sch&#xe4;fer A. Modulation of platelet and monocyte function by the chemokine fractalkine (CX3CL1) in cardiovascular disease. Eur J Clin Invest. (2015) 45:624&#x2013;33. 10.1111/eci.12443</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.12443</ArticleId><ArticleId IdType="pubmed">25832902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hundelshausen P v, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation. (2001) 103:1772&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11282909</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado MJ, Buend&#xed;a P, Velasco F, Aguirre MA, Barbarroja N, Torres LA, et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost. (2006) 4:2461&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16968331</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberale L, Carbone F, Montecucco F, Sahebkar A. Statins reduce vascular inflammation in atherogenesis: a review of underlying molecular mechanisms. Int J Biochem Cell Biol. (2020) 122:105735. 10.1016/j.biocel.2020.105735</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2020.105735</ArticleId><ArticleId IdType="pubmed">32126319</ArticleId></ArticleIdList></Reference><Reference><Citation>Francisci D, Pirro M, Schiaroli E, Mannarino MR, Cipriani S, Bianconi V, et al. Maraviroc intensification modulates atherosclerotic progression in HIV-suppressed patients at high cardiovascular risk. A randomized, crossover pilot study. Open Forum Infect Dis. (2019) 6:ofz112. 10.1093/ofid/ofz112</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofz112</ArticleId><ArticleId IdType="pmc">PMC6446135</ArticleId><ArticleId IdType="pubmed">30968058</ArticleId></ArticleIdList></Reference><Reference><Citation>Veenstra M, Le&#xf3;n-Rivera R, Li M, Gama L, Clements J, Berman J. Mechanisms of CNS viral seeding by HIV+ CD14+ CD16+ monocytes: establishment and reseeding of viral reservoirs contributing to HIV-associated neurocognitive disorders. mBio. (2017) 8:e1280&#x2013;1217. 10.1128/mBio.01280-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01280-17</ArticleId><ArticleId IdType="pmc">PMC5654927</ArticleId><ArticleId IdType="pubmed">29066542</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondal S, Rangasamy S, Roy A, Dasarathy S, Kordower J, Pahan K. Low-dose maraviroc, an antiretroviral drug, attenuates the infiltration of T-cells into the central nervous system and protects the nigrostriatum in hemiparkinsonian monkeys. J Immunol. (2019) 202:3412&#x2013;22. 10.4049/jimmunol.1800587</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1800587</ArticleId><ArticleId IdType="pmc">PMC6824976</ArticleId><ArticleId IdType="pubmed">31043478</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Chen S, Liu X, Zhang Q, Ai Y, Wang Y, et al. Flow-mediated vasodilation and endothelium function in children with postural orthostatic tachycardia syndrome. Am J Cardiol. (2010) 106:378&#x2013;82. 10.1016/j.amjcard.2010.03.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2010.03.034</ArticleId><ArticleId IdType="pubmed">20643249</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunning W, Stepkowski S, Kramer P, Karabin B, Grubb B. Inflammatory biomarkers in postural orthostatic tachycardia syndrome with elevated G-Protein-coupled receptor autoantibodies. J Clin Med. (2021) 10:623. 10.3390/jcm10040623</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10040623</ArticleId><ArticleId IdType="pmc">PMC7914580</ArticleId><ArticleId IdType="pubmed">33562074</ArticleId></ArticleIdList></Reference><Reference><Citation>Poniatowski &#x141;A, Wojdasiewicz P, Krawczyk M, Szukiewicz D, Gasik R, Kubaszewski &#x141;, et al. Analysis of the role of CX3CL2(Fractalkine) and its receptor CX3CR1 in traumatic brain and spinal cord injury: insight into recent advances in actions of neurochemokine agents. Mol Neurobiol. (2017) 54:2167&#x2013;88. 10.1007/s12035-016-9787-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-9787-4</ArticleId><ArticleId IdType="pmc">PMC5355526</ArticleId><ArticleId IdType="pubmed">26927660</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson PI, S&#xf8;rensen AM, Perner A, Welling K, Wanscher M, Larsen CF, et al. High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortality. J Thromb Haemost. (2012) 10:207&#x2013;16. 10.1111/j.1538-7836.2011.04589.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2011.04589.x</ArticleId><ArticleId IdType="pubmed">22151659</ArticleId></ArticleIdList></Reference><Reference><Citation>Oude Nijhuis C, Vellenga E, Daenen S, Kamps W, De Bont E. Endothelial cells are main producers of interleukin 8 through toll-like receptor 2 and 4 signaling during bacterial infection in leukopenic cancer patients. Clin Diagn Lab Immunol. (2003) 10:558&#x2013;63. 10.1128/cdli.10.4.558-563.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/cdli.10.4.558-563.2003</ArticleId><ArticleId IdType="pmc">PMC164273</ArticleId><ArticleId IdType="pubmed">12853386</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakoda K, Yamamoto M, Negishi Y, Liao J, Node K, Izumi Y. Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res. (2006) 85:520&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3001137</ArticleId><ArticleId IdType="pubmed">16723648</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani S, Francisci D, Mencarelli A, Renga B, Schiaroli E, D'Amore C, et al. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation. (2013) 127:2114&#x2013;24. 10.1161/CIRCULATIONAHA.113.001278</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.001278</ArticleId><ArticleId IdType="pubmed">23633271</ArticleId></ArticleIdList></Reference><Reference><Citation>Belge K, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol. (2002) 168:3536&#x2013;42. 10.4049/jimmunol.168.7.3536</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.7.3536</ArticleId><ArticleId IdType="pubmed">11907116</ArticleId></ArticleIdList></Reference><Reference><Citation>Dam&#xe5;s JK, Otterdal K, Yndestad A, Aass H, Solum NO, Fr&#xf8;land SS, et al. Soluble CD40 ligand in pulmonary arterial hypertension. Circulation. (2004) 110:999&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302794</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici R, Sofronski MD, Borboroglu P, Spirig AM, Hillegas LM, Levine J, et al. Interleukin-2-induced lung injury. The role of complement. Circ Res. (1994) 74:329&#x2013;35. 10.1161/01.res.74.2.329</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.res.74.2.329</ArticleId><ArticleId IdType="pubmed">8293571</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Kang H, Jhon M, Kim J, Lee J, Walker A, et al. Statins and inflammation: new therapeutic opportunities in psychiatry. Front Psychiatry. (2019) 10:103. 10.3389/fpsyt.2019.00103</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2019.00103</ArticleId><ArticleId IdType="pmc">PMC6413672</ArticleId><ArticleId IdType="pubmed">30890971</ArticleId></ArticleIdList></Reference><Reference><Citation>Giaquinto C, Mawela MP, Chokephaibulkit K, Negra MD, Mitha IH, Fourie J, et al. Pharmacokinetics, safety and efficacy of maraviroc in treatment-experienced pediatric patients infected with CCR5-tropic HIV-1. Pediatr Infect Dis J. (2018) 37:459&#x2013;65. 10.1097/INF.0000000000001808</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000001808</ArticleId><ArticleId IdType="pmc">PMC5916460</ArticleId><ArticleId IdType="pubmed">29023357</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulick RM, Fatkenheuer G, Burnside R, Hardy WD, Nelson MR, Goodrich J, et al. Five-year safety evaluation of maraviroc in HIV-1&#x2013;infected treatment-experienced patients. J Acquir Immune Defic Syndr. (2014) 65:78&#x2013;81. 10.1097/QAI.0b013e3182a7a97a</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAI.0b013e3182a7a97a</ArticleId><ArticleId IdType="pmc">PMC3893710</ArticleId><ArticleId IdType="pubmed">24419064</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoub A, Alston S, Goodrich J, Heera J, Hoepelman A, Lalezari J, et al. Hepatic safety and tolerability in the maraviroc clinical development program. AIDS. (2010) 24:2743&#x2013;50. 10.1097/QAD.0b013e32833f9ce2</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0b013e32833f9ce2</ArticleId><ArticleId IdType="pubmed">20935557</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>